At the annual congress of the European Society for Medical Oncology (ESMO), Seagen and Astellas Pharma have presented detailed data from the Phase III EV-302 study. 23 October 2023
Enhertu (trastuzumab deruxtecan) has been approved in the European Union (EU) as monotherapy for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC). 23 October 2023
UK pharma major GSK has entered into an exclusive license agreement with Chinese biopharma firm Hansoh Pharma for HS-20089, a B7-H4 targeted antibody-drug conjugate (ADC) currently in Phase I (NCT05263479) clinical trials in China. 21 October 2023
Shares of Japanese pharma major Daiichi Sankyo soared 14.4% to 4,095 yen by close of Tokyo trading today, after it announced what, if all goes according to plan, could be the biggest pharma licensing deal ever seen. 20 October 2023
Osaka, Japan-based biotech RegCell today announced the appointment of experienced life science exec Michael McCullar, as its new president, chief executive and representative director. 19 October 2023
Singapore-based biotech Hummingbird Bioscience today announced that San Diego, USA-based Endeavor BioMedicines has acquired exclusive worldwide rights to Hummingbird’s antibody-drug conjugate (ADC), HMBD-501. 19 October 2023
Japanese drugmaker Daiichi Sankyo revealed that it has been ordered by a Texas district court to pay royalties on its antibody-drug conjugate (ADC) to US biotech Seagen. 19 October 2023
Elevar Therapeutics and Hengrui Pharma have agreed to a global licensing deal giving the former rights to commercialize and develop the checkpoint blocker camrelizumab. 18 October 2023
Sino-American biotech BeiGene became the first Chinese-origin pharma company to market a programmed cell death protein 1 (PD1) therapy for oncology indications in various global markets, beginning with the European Union. 18 October 2023
Japanese drugmaker Takeda has announced that the Phase III ADMIRE-CD II study of Alofisel (darvadstrocel) in complex Crohn’s perianal fistulas (CPF) failed to meet its primary endpoint of combined remission at 24 weeks, based on topline data. 18 October 2023
China-headquartered independent biotech MediLink Therapeutics has entered into a strategic research collaboration and worldwide license agreement with Germany’s BioNTech on the development of a next-generation antibody-drug conjugate (ADC) candidate against human epidermal growth factor receptor 3 (HER3). 13 October 2023
China’s CARsgen Therapeutics has announced the publication of two cases of long-term disease-free survival in the treatment of advanced hepatocellular carcinoma (HCC) with its CAR-GPC3 T-cell therapy. 12 October 2023
Israel-based cancer and rare diseases drug developer BioLineRx today announced the closing of an exclusive license agreement with Guangzhou Gloria Biosciences (GloriaBio) and an associated investor for the development of motixafortide across all indications in Asia, with the news sending BioLineRx’ shares up 6.7% to $1.60. 12 October 2023
One big challenge for pharma companies doing cross-border businesses in China and the USA is the respective cybersecurity law imposed by the two countries. 12 October 2023
Patrick Branch, a Japan-based strategy consultant from LEK Consulting, provides an Expert View on the ‘new map’ for healthcare firms in Asia. 11 October 2023
BioMap today announced a ground-breaking strategic collaboration with French pharma major Sanofi to co-develop cutting-edge artificial intelligence (AI) modules for biologic therapies leveraging BioMap’s AI platform. 11 October 2023
Shares of Chinese high-tech biological enterprise Chongqing Zhifei Biological Products leapt 20% to 58.40 renminbi, on the news that it will to co-promote UK pharma major GSK's shingles vaccine, Shingrix. 9 October 2023
Caught up in the geopolitical tension between China and the West, western pharma multi-national corporations (MNCs) are increasingly cautious about investing in China. 5 October 2023
Shares of US and UK-based gene therapy company Orchard Therapeutics almost doubled to $16.03 in pre-market activity today, on the news that it has received a takeover offer from mid-size Japanese drugmaker Kyowa Kirin. 5 October 2023
Daiichi Sankyo’s today revealed that its Vanflyta (quizartinib) has been recommended by the National Institute for Health and Care Excellence (NICE) for routine National Health Service (NHS) commissioning in England and Wales. 19 September 2024
Gene therapy research in Japan has gained significant momentum due to the SAKIGAKE designation system and government-led initiatives like the “Project for Regenerative/Cellular Medicine and Gene Therapies” to accelerate research and development (R&D) to create new technologies for gene/cell therapy. 18 September 2024
The HERTHENA-Lung02 Phase III trial of patritumab deruxtecan, in patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) who received prior EGFR tyrosine kinase inhibitor (TKI) treatment, has met its primary endpoint. 17 September 2024
US biotech Capricor Therapeutics has entered into a binding term sheet with Japanese drugmaker Nippon Shinyaku for the commercialization and distribution in Europe of Capricor’s lead asset, deramiocel. 17 September 2024
Women’s health focussed company Organon China today revealed that it has entered into license and supply agreements with Shanghai Bao Pharmaceutical, acquiring the exclusive commercialization rights to its investigational asset, SJ02, in China Mainland. 13 September 2024
On Thursday, the US Food and Drug Administration released a Drug Safety Communication warning that Veozah (fezolinetant), which is used to treat hot flashes due to menopause, can cause rare but serious liver injury. 13 September 2024
NewCo, a relatively new business model that involves a joint venture (JV) between a biotech and a group of investors to bring the biotech’s promising assets to the global market, is gaining popularity among Chinese biotechs, who traditionally rely on out-licensing deals to capitalize assets, s 11 September 2024
Detailed results were released from the TROPION-Lung01 Phase III trial, which showed a clinically meaningful trend toward improving overall survival (OS) with datopotamab deruxtecan (Dato-DXd) compared to docetaxe. 10 September 2024
Chinese companies Innovent Biologics and GenFleet have recently secured approval from China’s National Medical Products Administration (NMPA) for Dupert (fulzerasib). 9 September 2024
Summit Therapeutics on Sunday announced data from the primary analysis of the Phase III HARMONi-2 trial featuring the novel, potential first-in-class investigational bispecific antibody, ivonescimab compared to Merck & Co’s) mega blockbuster drug Keytruda (pembrolizumab). 9 September 2024
Organon KK, a Japan subsidiary of Organon & Co, announced that the primary endpoint was achieved in a domestic Phase III clinical trial evaluating the efficacy and safety of OG-8276A 6 September 2024
Targeted alpha therapy (TAT), or radioligand therapy, is a recent hot area that attracted big pharmas like Bristol Myers Squibb and Novartis. 5 September 2024
Biosimilar-focused biopharmaceutical company and contract development and manufacturing organization (CDMO) Tanvex BioPharma has named Stephen Lam its new chief executive (CEO). 5 September 2024
Privately-held Chinese biotech EpimAb Biotherapeutics and Vignette Bio have entered into a license agreement for EpimAb’s BCMA-targeting T-cell engager (TCE) EMB-06. 5 September 2024
Rigel Pharmaceutical’s shares dipped 4.4% to $12 .85 by late morning, despite announcing what could be a lucrative deal for the company. 3 September 2024
Chinese gene therapy specialist YolTech Therapeutics has entered into an exclusive licensing agreement with Salubris Pharmaceuticals (SHE: 002294). 3 September 2024
Japan’s Nxera Pharma today announced that it will receive a $35 million payment from Neurocrine Biosciences, triggered by the successful completion of the Phase II trial with NBI-1117568 (NBI-‘568) in adults with schizophrenia. 2 September 2024
Chinese biopharma Hutchmed on Friday announced that it has voluntarily withdrawn its supplemental New Drug Application (NDA) in China for fruquintinib. 2 September 2024
Jacobio Pharma announced that it has granted the China rights to KRAS G12C inhibitor glecirasib and SHP2 inhibitor JAB-3312 to Shanghai Allist Pharmaceuticals. 2 September 2024